- ¥1tn
- ¥997bn
- ¥497bn
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia
Lilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
Brief: FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
Table: Kyowa Kirin -Q1 group results (IFRS)
Gallo buys Four Roses bourbon from Japan's Kirin
Table: Kyowa Kirin -2025 parent results
Table: Kyowa Kirin -2025 group results (IFRS)
Kyowa Kirin stops development of skin condition treatment (updated)
Kyowa Kirin stops development of skin condition treatment
Brief: Kyowa Kirin Announces Discontinuation Of Rocatinlimab Clinical Trials
Table: Kyowa Kirin -2025 group results (IFRS)
Table: Kyowa Kirin -2025 parent results
Japan's Kirin to sell Four Roses bourbon brand to Gallo for $775 million (updated)
Notice Regarding Change In Management Structure (CEO Succession
Brief: Kura Oncology & Kyowa Kirin Announce Positive KOMZIFTI Combination Data for acute myeloid
Brief: KOMZIFTI Gets FDA Approval For Adults With Relapsed Or Refractory NPM1-Mutated AML